Medicare will expand coverage for obesity drugs starting mid-2026 after a landmark deal with Eli Lilly and Novo Nordisk, making weight loss medications more affordable for about 7.4 million beneficiaries with obesity and related conditions. Copays will drop to around $50 monthly, down from up to $1,350. The agreement includes price cuts, tariff exemptions, and faster drug approvals, aiming to improve health outcomes and reduce costs.
Continue to full article
Leave a Reply